Message from the Guest Editors

Dear Colleagues,

Antibodies are an important and vital constituent of adaptive immunity, with the potential to recognize an essentially unlimited set of foreign molecules (antigens). Antibodies are rapidly made in response to infections and, therefore, they have immense diagnostic value.

Finally, due to their specificity and versatility, tailor-made Abs, mainly in the form of monoclonal Abs, can be used diagnostically for measurement of a wide range of analytes/targets, most often in the form of sandwich immunoassays, immunocytochemistry/immunohistochemistry and flow-based cell assays. Such assays are continuously being refined and combined with other techniques, e.g. mass spectrometry, PCR, etc., making Ab-based diagnostics the most important technique in many areas of bio-medicine.

This Special Issue on antibody-based diagnostics aims to describe current state-of-the-art techniques and applications, as well as newer and emerging uses of antibodies in diagnostics.

Prof. Gunnar Houen
Dr. Nicole Hartwig Trier
Guest Editor
Editor-in-Chief

Prof. Dr. Dimiter S. Dimitrov
Center for Antibody Therapeutics, University of Pittsburgh Medical School, Pittsburgh, PA 15213, USA

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: Indexed in the Emerging Sources Citation Index (ESCI - Web of Science), EMBASE (Elsevier) and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 14.1 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Antibodies
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

antibodies@mdpi.com